Molnulup 200mg Capsule
Product Info
| Prescription required | Yes |
| Marketer | Lupin Ltd |
| Active Ingredient | Molnupiravir (200mg) |
| Chemical Class | Cytosine Nucleotides |
| Habit Forming | No |
| Therapeutic Class | ANTI INFECTIVES |
| Action Class | Antiviral (Non-HIV) drugs |
| User Rating | 4.8 |
| User Reviews | 759 |
FAQ
Who should not take Molnulup 200mg?
Molnulup 200mg should not be taken to prevent COVID-19 or treat patients hospitalized due to COVID-19. According to the ongoing clinical trials, patients hospitalized with severe COVID-19 infection have not benefited from taking Molnulup 200mg.
Who is at a high risk of developing severe COVID-19?
People who are at a high risk of developing severe COVID-19 include those aged above 60 years, who are obese, have comorbid conditions including high blood pressure, diabetes, asthma, other medical conditions related to the lungs, kidneys (like dialysis patients), liver, or those who have a weak immunity (like cancer patients).
Is taking Molnulup 200mg better than getting vaccinated?
No. There is no comparison between the two, and Molnulup 200mg is not a substitute for getting vaccinated. Vaccination is for prevention, while Molnulup 200mg is used to treat an existing COVID-19 infection, provided the infection is diagnosed at an early stage.
Can Molnulup 200mg be given to children?
No, Molnulup 200mg is not approved for use in children or patients below the age of 18 years as it may interfere with the growth of bones and cartilage.
Are there any serious risks of taking Molnulup 200mg?
Yes, there are some serious risks involved with using Molnulup 200mg, including its potential to cause birth defects in pregnant women and serious damage to the growth of bones and cartilage (which may cause serious muscle damage). Therefore, Molnulup 200mg should be used only if prescribed by a doctor and not used for self-medication.
What is the advantage of using Molnulup 200mg?
Molnulup 200mg has better patient compliance than some other treatment options available against COVID-19. Unlike other medicines that may need a skilled healthcare professional (a doctor or a nurse) to administer, Molnulup 200mg is an oral medicine that can be consumed by mouth in the dosage and schedule prescribed by the doctor.
What if you forget to take Molnulup Capsule?
If you miss a dose of Molnulup 200mg, please consult your doctor.
Molnulup 200mg Capsule Reviews
Molnulup 200mg is the first oral antiviral medication that helps treat mild to moderate COVID-19 in adults. It prevents the virus from multiplying, thereby reducing viral load and disease severity. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021.
Molnulup 200mg is only indicated in patients with mild to moderate COVID-19 symptoms and who have a high risk of developing severe symptoms. The risk factors include obesity, older age (>60 years), diabetes mellitus, and heart diseases. It is not indicated in patients who require immediate hospitalization due to COVID-19. This drug has also been approved by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency for emergency use.
Molnulup 200mg should be taken orally for no longer than 5 consecutive days. It is important to complete the entire 5 days of treatment, therefore do not stop taking it even if you feel better. The medicine may cause dizziness, headache, diarrhea, and nausea in some patients. If one experiences any such side effects, discuss them with the doctor. They may help with the treatment or suggest ways to prevent them.
Before taking Molnulup 200mg, let the doctor know if you have any pre-existing medical conditions. To make sure it is safe for you, inform your doctor about all the other medications you are taking. The use of Molnulup 200mg is not recommended in pregnant women. Pregnant and breastfeeding women should consult with their doctors before taking this medicine.
Molnulup 200mg is only indicated in patients with mild to moderate COVID-19 symptoms and who have a high risk of developing severe symptoms. The risk factors include obesity, older age (>60 years), diabetes mellitus, and heart diseases. It is not indicated in patients who require immediate hospitalization due to COVID-19. This drug has also been approved by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency for emergency use.
Molnulup 200mg should be taken orally for no longer than 5 consecutive days. It is important to complete the entire 5 days of treatment, therefore do not stop taking it even if you feel better. The medicine may cause dizziness, headache, diarrhea, and nausea in some patients. If one experiences any such side effects, discuss them with the doctor. They may help with the treatment or suggest ways to prevent them.
Before taking Molnulup 200mg, let the doctor know if you have any pre-existing medical conditions. To make sure it is safe for you, inform your doctor about all the other medications you are taking. The use of Molnulup 200mg is not recommended in pregnant women. Pregnant and breastfeeding women should consult with their doctors before taking this medicine.
How Molnulup 200mg Capsule Works
Molnulup 200mg is an antiviral medicine. It works by inhibiting the SARS-CoV-2 virus from replicating. This stops the virus from producing new copies and hence decreases the viral load in the body.
How to Use Molnulup 200mg Capsule
Take this medicine in the dose and duration as advised by your doctor. Molnulup 200mg may be taken with or without food, but it is better to take it at a fixed time.
Benefits of Molnulup 200mg Capsule
- In Treatment of Mild to moderate Coronavirus disease (COVID-19): Molnulup 200mg helps manage mild to moderate Covid-19 symptoms in those individuals who are at a high risk of developing severe Covid-19 disease and do not need oxygen administration. This medicine may help you recover from the infection if diagnosed early before hospitalization. If you think you have come in contact with a person who has been infected with Covid-19, or if you feel any of these symptoms, consult your doctor immediately.
Uses of Molnulup 200mg Capsule
- Treatment of Mild to moderate Coronavirus disease (COVID-19)
Molnulup 200mg Capsule Side Effects
Safety Tips
Kidney
SAFE IF PRESCRIBED
Molnulup 200mg is safe to use in patients with kidney disease. No dose adjustment of Molnulup 200mg is recommended.
Alcohol
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Molnulup 200mg. Please consult your doctor.
Driving
CONSULT YOUR DOCTOR
It is not known whether Molnulup 200mg alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Pregnancy
CONSULT YOUR DOCTOR
Molnulup 200mg may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Liver
SAFE IF PRESCRIBED
Molnulup 200mg is safe to use in patients with liver disease. No dose adjustment of Molnulup 200mg is recommended.
Breast feeding
UNSAFE
Molnulup 200mg is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Quick Tips
- For individuals with conceiving potential, it is advisable to use contraceptive methods while taking Molnupiravir and for 4 days after the last dose of the medicine.
- Do not give Molnulup 200mg to children and adolescents aged less than 18 years.
- Even after the treatment, continue practicing COVID-appropriate behavior such as wearing a mask, social distancing, and frequent handwashing.
- Do not stop taking Molnulup 200mg without talking to your doctor first, as it will protect you from becoming severely ill from COVID-19.
References
- Molnupiravir [Package leaflet: Information for the patient]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021.
- Molnupiravir [EMC SmPC]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021.
- EUnetHTA Rolling Collaborative Review (RCR19) Authoring Team. Molnupiravir for the treatment of COVID-19. Diemen (The Netherlands): EUnetHTA; 2020. Report No.: RCR19, v1.0.
- Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India. Sun Pharma: Press Release.
- FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. December 23, 2021.
- European Medicines Agency. Assessment Report: Use of molnupiravir for the treatment of COVID-19.
- Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-746.
- Molnupiravir. U.S. Food & Drug Administration Antimicrobial Drugs Advisory Committee November 30, 2021.
- Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu®(Molnupiravir 200mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and with high risk of disease progression including hospitalization or death. Cipla: Press Statement.
- U.S. Food and Drug Administration: Center for Drug Evaluation and Research FDA Briefing Document, Antimicrobial Drugs Advisory Committee Meeting, November 30, 2021.